OncLive TV

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses the promising results and future investigation of MET inhibition in hepatocellular carcinoma using cabozantinib and tivantinib.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes results from the 301 Study that compared eribulin mesylate to capecitabine for locally advanced or metastatic breast cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses c-MET inhibition in hepatocellular carcinoma.

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

Eleftherios (Terry) P. Mamounas, MD, MPH, from the Aultman Hospital Cancer Center, discusses the controversial topic of surgery for patients who present with stage IV breast cancer at the time of diagnosis.

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

James C. Yao, MD, from the MD Anderson Cancer Center, describes the administration of the mTOR inhibitor everolimus in patients with pancreatic neuroendocrine tumors.

Jorge E. Cortes, MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, discusses the use of ponatinib as initial therapy for patients with chronic myeloid leukemia.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the final analysis of overall survival for the phase III CONFIRM trial.

Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma.

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia.

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes results from the phase III COUGAR-02 study that examined second-line docetaxel in patients with advanced gastroesophageal adenocarcinoma.

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

William T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.